Corporate Banner
Satellite Banner
Technology Networks Header
Wednesday, September 17, 2014
Technology Networks
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
Study Aims to Develop Breath Test for COPD
A new clinical iniative, lead by NYU Langone Medical Center, aims to determine a breath test’s effectiveness to identify volatile organic compounds (VOCs) in human breath that are biomarkers of chronic obstructive pulmonary disease (COPD).
In Directing Stem Cells, Context Matters
The surface cells are grown on has a profound effect on differentiation.
New Cell Model to Speed up Development of Brain Tumour Drugs
Rresearch looks set to improve screening for new cancer drugs and drug delivery systems specifically designed for children with brain tumours.
New Advances in the Pre-clinical Evaluation of Hepatitis B Therapies
Imperial College London to present first public HBV Data from CN Bio in vitro liver model.
Cancer-Fighting Drugs Might Also Stop Malaria Early
A number of compounds have been identified which could be used to fight malaria.
Bowel Disease Gene Discovery
Genetic changes that occur in patients with the bowel condition Crohn’s disease could hold clues to fighting the illness.
Test Reliably Detects Inherited Immune Deficiency in Newborns
NIH-supported study suggests that early diagnosis of severe combined immunodeficiency leads to high survival rates.
Test Reliably Detects Inherited Immune Deficiency in Newborns
NIH-supported study suggests that early diagnosis of severe combined immunodeficiency leads to high survival rates.
Heart Molecule Discovery Could Lead to Effective Treatment for Heart Failure
Researchers have discovered a previously unknown cardiac molecule that could provide a key to treating, and preventing, heart failure.
UK Government Must Do More to Reduce Risk of vCJD Infection
Report recommends that UK Government commission a full assessment of the risks currently faced by the UK blood supply.
Scroll Up
Scroll Down
Return
Cardiac Ion Channel Safety Profiling: Integrated Risk Assessment for hERG and Beyond
Gul Erdemli, Novartis, Head of Ion Channel Group, speaking at Ion Channel Targets 2010.
Date Posted: Friday, November 26, 2010
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



Novartis Provides Drug Candidate Compounds to TB Alliance
Exclusive worldwide license from Novartis includes a novel class of drugs that is active against drug sensitive and multi-resistant strains of tuberculosis.
Wednesday, August 20, 2014
Novartis Announces Portfolio Transformation
Company launches a major overhaul of its business, unveiling a series of multibillion-dollar deals with GSK and Eli Lilly.
Wednesday, April 23, 2014
Nuevolution Announces New Research Collaboration with Big Pharma
Partnership to use Nuevolution's Chemetics® technology for lead discovery.
Tuesday, September 01, 2009
FORMA Announces Collaboration with Novartis to Develop Inhibitors of Protein-Protein Interactions
FORMA will leverage its expertise to develop inhibitors for an undisclosed protein-protein interaction target in the field of oncology.
Tuesday, January 13, 2009
 

Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv